Hida Toyoaki, Kozaki Ken-Ichi, Ito Hidemi, Miyaishi Osamu, Tatematsu Yoshio, Suzuki Takeshi, Matsuo Keitaro, Sugiura Takahiko, Ogawa Makoto, Takahashi Toshitada, Takahashi Takashi
Department of Internal Medicine, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Clin Cancer Res. 2002 Jul;8(7):2443-7.
This study reports that a selective COX-2 inhibitor JTE-522inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC(50)s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.
本研究报告称，选择性COX - 2抑制剂JTE - 522作为单一药物可抑制人肺癌细胞的体外和体内生长。此外，JTE - 522的辅助使用不仅在体外而且在体内均显示出可显著提高传统抗癌药物的治疗效果，且未引起任何明显的副作用。事实上，各种抗癌药物的体外半数抑制浓度（IC50）降低了多达70%，而JTE - 522与多西他赛和长春瑞滨的联合治疗在体内分别抑制肿瘤生长65%和55%。综上所述，这些发现表明，使用选择性COX - 2抑制剂治疗肺癌可能很有前景，特别是因为它在不影响生活质量的情况下提高了传统抗癌药物的治疗效果。
